(Q35533579)

8 August 2017

title

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial (English)

1 reference

8 August 2017

0 references

10

Lixin Zhang-Auberson

1 reference

8 August 2017

Philipp von Rosenstiel

series ordinal

9

object named as

Philipp von Rosenstiel

1 reference

8 August 2017

1

Ludwig Kappos

1 reference

8 August 2017

6

Krzysztof Selmaj

1 reference

8 August 2017

3

Ernst-Wilhelm Radue

1 reference

8 August 2017

4

Chris Polman

1 reference

8 August 2017

5

Reinhard Hohlfeld

1 reference

8 August 2017

7

Shannon Ritter

1 reference

8 August 2017

Paul O'Connor

2

1 reference

8 August 2017

Rolf Schlosshauer

series ordinal

8

1 reference

8 August 2017

Gordon Francis

series ordinal

11

1 reference

8 August 2017

language of work or name

English

0 references

publication date

20 March 2015

1 reference

8 August 2017

1 reference

8 August 2017

volume

84

1 reference

8 August 2017

issue

15

1 reference

8 August 2017

page(s)

1582-1591

1 reference

Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings

8 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

Oral fingolimod (FTY720) for relapsing multiple sclerosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

ICH harmonized tripartite guideline: Guideline for Good Clinical Practice.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4408283

World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects

15 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25795646

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0000000000001462

1 reference

8 August 2017

1 reference

8 August 2017

1 reference